In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (479 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 5.036, 5-year impact factor: 4.665
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-77954960181&partnerID=40&md5=32034d04a14dafa665642826b88536d7
Keywords: 111in-Pentetreotide Scintigraphy, Indications, Neuroendocrine Tumours, Procedure Guidelines, Tumour Imaging, Dota Noc Ga 68, Dota Tate Ga 68, Dota Toc Ga 68, Gastrin, Glucagon, Glucose, Insulin, Pentetreotide In 111, Radioisotope, Radiopharmaceutical Agent, Somatostatin, Somatostatin Derivative, Somatostatin Receptor, Unclassified Drug, Diagnostic Agent, Drug Derivative, Age Distribution, Astrocytoma, Autoimmune Disease, Bacterial Infection, Breast, Breast Cancer, Breast Carcinoma, Breast Feeding, Cancer Chemotherapy, Cancer Localization, Cancer Radiotherapy, Cancer Staging, Cancer Surgery, Cecum, Colon, Diabetes Mellitus, Diabetic Patient, Diagnostic Accuracy, Diagnostic Imaging, Drug Accumulation, Drug Clearance, Drug Distribution, Drug Elimination, Drug Megadose, Drug Quality, Drug Receptor Binding, Drug Uptake, Drug Withdrawal, Endocrine Ophthalmopathy, False Negative Result, False Positive Result, Follow Up, Gallbladder, Ganglioneuroma, Gastrin Blood Level, Gastrinoma, Glucagon Blood Level, Glucagonoma, Glucose Metabolism, Granuloma, Human, Hypoglycemia, Hypophysis Adenoma, Image Analysis, Image Processing, Inflammatory Disease, Insulinoma, Intestine Injury, Kidney, Kidney Carcinoma, Kidney Dysfunction, Liver, Liver Metastasis, Lung Non Small Cell Cancer, Lung Small Cell Cancer, Lymphocyte, Medical Examination, Melanoma, Meningioma, Merkel Cell Tumor, Molecular Imaging, Neoplasm, Neuroblastoma, Nuclear Medicine, Paraganglioma, Parenteral Nutrition, Patient Monitoring, Patient Selection, Pheochromocytoma, Physician, Pleura, Practice Guideline, Pregnancy, Prognosis, Prostate Carcinoma, Protein Expression, Quality Control, Radiation Dose Distribution, Radioactivity, Radioisotope Therapy, Review, Sarcoma, Scintillation Camera, Single Photon Emission Computer Tomography, Spleen, Therapeutic Error, Thyroid Carcinoma, Thyroid Medullary Carcinoma, Treatment Contraindication, Treatment Indication, Tumor Differentiation, Tumor Scintiscanning, Undifferentiated Carcinoma, Urinary Excretion, Vipoma, Article, Computer Assisted Diagnosis, Female, Gene Expression Regulation, Genetics, Instrumentation, Methodology, Gamma Cameras, Neoplastic, Image Interpretation, Computer-Assisted, Radionuclide Imaging, Research Design,
Affiliations:
*** IBB - CNR ***
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Nuclear Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
University, Kocaeli, Turkey
PET Center, Bad Berka, Germany
CHUV, Lausanne, Switzerland
University of Naples, Naples, Italy
Ospedale di Legnano, Legnano, Italy
University UZ Gasthuisberg, Louvain, Belgium
Radboud University, Nijmegen, Netherlands
Istituto Clinico Humanitas, Milan, Italy
References:
Balon, H.R., Goldsmith, S.J., Siegel, B.A., Silberstein, E.B., Krenning, E.P., Lang, O., Procedure guideline for somatostatin receptor scintigraphy with (111) In-pentetreotide (2001) J. Nucl. Med., 42 (7), pp. 1134-113
Kwekkeboom, D.J., Krenning, E.P., Scheidhauer, K., Lewington, V., Lebtahi, R., Grossman, A., ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Somatostatin receptor imaging with (111)In-pentetreotide (2009) Neuroendocrinology, 90 (2), pp. 184-189
Lamberts, S.W., Bakker, W.H., Reubi, J.C., Krenning, E.P., Somatostatin-receptor imaging in the localization of endocrine tumors (1990) N. Engl. J. Med., 323 (18), pp. 1246-1249
Seregni, E., Chiti, A., Bombardieri, E., Radionuclide imaging of neuroendocrine tumours: Biological basis and diagnostic results (1998) Eur. J. Nucl. Med., 25 (6), pp. 639-658
Krenning, E.P., Kwekkeboom, D.J., Bakker, W.H., Breeman, W.A., Kooij, P.P., Oei, H.Y., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam expe-rience with more than 1000 patients (1993) Eur. J. Nucl. Med., 20 (8), pp. 716-731
Jamar, F., Fiasse, R., Leners, N., Pauwels, S., Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: Safety, efficacy and impact on patient management (1995) J. Nucl. Med., 36 (4), pp. 542-549
Olsen, J.O., Pozderac, R.V., Hinkle, G., Hill, T., O'Dorisio, T.M., Schirmer, W.J., Somatostatin receptor imaging of neuroendo-crine tumors with indium-111 pentetreotide (Octreoscan) (1995) Semin. Nucl. Med., 25 (3), pp. 251-261
Asnacios, A., Courbon, F., Rochaix, P., Bauvin, E., Cances-Lauwers, V., Susini, C., Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: New prognostic factors for malignant well-differentiated endocrine tumors (2008) J. Clin. Oncol., 26 (6), pp. 963-970
Wong, K.K., Cahill, J.M., Frey, K.A., Avram, A.M., Incremental value of 111-In pentetreotide SPECT/CT fusion imaging of neuroendo-crine tumors (2010) Acad. Radiol., 17, pp. 291-297
Steffen, I.G., Mehl, S., Heuck, F., Elgeti, F., Furth, C., Amthauer, H., Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: Is there an impact on sensitivity? (2009) Clin. Nucl. Med., 34 (12), pp. 869-873
Krausz, Y., Keidar, Z., Kogan, I., Even-Sapir, E., Bar-Shalom, R., Engel, A., SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours (2003) Clin. Endocrinol. (Oxf), 59 (5), pp. 565-573
Schillaci, O., Scopinaro, F., Angeletti, S., Tavolaro, R., Danieli, R., Annibale, B., SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors (1996) J. Nucl. Med., 37 (9), pp. 1452-1456
Warner, R.R., O'dorisio, T.M., Radiolabeled peptides in diagnosis and tumor imaging: Clinical overview (2002) Semin. Nucl. Med., 32 (2), pp. 79-83
Westlin, J.E., Janson, E.T., Arnberg, H., Ahlström, H., Oberg, K., Nilsson, S., Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide (1993) Acta Oncol., 32 (7-8), pp. 783-786
Schmidt, M., Scheidhauer, K., Luyken, C., Voth, E., Hildebrandt, G., Klug, N., Somatostatin receptor imaging in intracranial tumours (1998) Eur. J. Nucl. Med., 25 (7), pp. 675-686
Pichler, R., Pichler, J., Mustafa, H., Nussbaumer, K., Zaunmüller, T., Topakian, R., Somatostatin-receptor positive brain stem glioma visualized by octreoscan (2007) Neuro. Endocrinol. Lett., 28 (3), pp. 250-251
Kälkner, K.M., Janson, E.T., Nilsson, S., Carlsson, S., Oberg, K., Westlin, J.E., Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radioligand uptake and tumor markers (1995) Cancer Res., 55 (23 SUPPL.), pp. 5801s-5804s
Gibril, F., Reynolds, J.C., Doppman, J.L., Chen, C.C., Venzon, D.J., Termanini, B., Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study (1996) Ann. Intern. Med., 125 (1), pp. 26-34
Briganti, V., Sestini, R., Orlando, C., Bernini, G., La Cava, G., Tamburini, A., Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determina-tion of somatostatin receptor type 2 gene expression in neuroblastoma tumors (1997) Clin. Cancer Res., 3 (1-12 PT.), pp. 2385-2391
Chiti, A., Briganti, V., Fanti, S., Monetti, N., Masi, R., Bombardieri, E., Results and potential of somatostatin receptor imaging in gastro-enteropancreatic tract tumours (2000) Q J. Nucl. Med., 44 (1), pp. 42-49
Chiti, A., Fanti, S., Savelli, G., Romeo, A., Bellanova, B., Rodari, M., Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours (1998) Eur. J. Nucl. Med., 25 (10), pp. 1396-1403
Lebtahi, R., Cadiot, G., Sarda, L., Daou, D., Faraggi, M., Petegnief, Y., Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancre-atic tumors (1997) J. Nucl. Med., 38 (6), pp. 853-858
Khanna, G., O'Dorisio, M.S., Menda, Y., Glasier, C., Deyoung, B., Smith, B.J., Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies (2008) Pediatr. Blood Cancer, 50 (3), pp. 561-566
Kropp, J., Hofmann, M., Bihl, H., Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor? (1997) Anti-cancer Res., 17 (3 B), pp. 1583-1588
Radiation dose to patients from radio-pharmaceuticals (1998) Ann. ICRP, 28, p. 3. , ICRP Publication 80, Oxford: Pergamon
Radiological protection in biomedical research (1991) Ann. ICRP, 22, p. 3. , ICRP Publication 62, Oxford: Pergamon
(2008) Ann. ICRP, 38 (1-2), pp. 1-197. , Radiation dose to patients from radiopharmaceuticals, Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007
Sokole, E.B., Plachcínska, A., Britten, A., EANM working group on nuclear medicine instrumentation quality control, Lyra Georgosopoulou M, et al. Routine quality control recommendations for nuclear medicine instrumentation (2010) Eur. J. Nucl. Med. Mol. Imaging, 37, pp. 662-671. , EANM Physics Committee
Balon, H. R., Goldsmith, S. J., Siegel, B. A., Silberstein, E. B., Krenning, E. P., Lang, O., Procedure guideline for somatostatin receptor scintigraphy with (111) In-pentetreotide (2001) J. Nucl. Med., 42 (7), pp. 1134-113
Kwekkeboom, D. J., Krenning, E. P., Scheidhauer, K., Lewington, V., Lebtahi, R., Grossman, A., ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Somatostatin receptor imaging with (111) In-pentetreotide (2009) Neuroendocrinology, 90 (2), pp. 184-189
Lamberts, S. W., Bakker, W. H., Reubi, J. C., Krenning, E. P., Somatostatin-receptor imaging in the localization of endocrine tumors (1990) N. Engl. J. Med., 323 (18), pp. 1246-1249
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A., Kooij, P. P., Oei, H. Y., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1] -and [123I-Tyr3] -octreotide: The Rotterdam expe-rience with more than 1000 patients (1993) Eur. J. Nucl. Med., 20 (8), pp. 716-731
Olsen, J. O., Pozderac, R. V., Hinkle, G., Hill, T., O'Dorisio, T. M., Schirmer, W. J., Somatostatin receptor imaging of neuroendo-crine tumors with indium-111 pentetreotide (Octreoscan) (1995) Semin. Nucl. Med., 25 (3), pp. 251-261
Wong, K. K., Cahill, J. M., Frey, K. A., Avram, A. M., Incremental value of 111-In pentetreotide SPECT/CT fusion imaging of neuroendo-crine tumors (2010) Acad. Radiol., 17, pp. 291-297
Steffen, I. G., Mehl, S., Heuck, F., Elgeti, F., Furth, C., Amthauer, H., Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: Is there an impact on sensitivity? (2009) Clin. Nucl. Med., 34 (12), pp. 869-873
Warner, R. R., O'dorisio, T. M., Radiolabeled peptides in diagnosis and tumor imaging: Clinical overview (2002) Semin. Nucl. Med., 32 (2), pp. 79-83
Westlin, J. E., Janson, E. T., Arnberg, H., Ahlstr m, H., Oberg, K., Nilsson, S., Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1] -octreotide (1993) Acta Oncol., 32 (7-8), pp. 783-786
K lkner, K. M., Janson, E. T., Nilsson, S., Carlsson, S., Oberg, K., Westlin, J. E., Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radioligand uptake and tumor markers (1995) Cancer Res., 55 (23 SUPPL.), pp. 5801s-5804s
(2008) Ann. ICRP, 38 (1-2), pp. 1-197. , Radiation dose to patients from radiopharmaceuticals, Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007
Sokole, E. B., Plachc nska, A., Britten, A., EANM working group on nuclear medicine instrumentation quality control, Lyra Georgosopoulou M, et al. Routine quality control recommendations for nuclear medicine instrumentation (2010) Eur. J. Nucl. Med. Mol. Imaging, 37, pp. 662-671. , EANM Physics Committee
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 5.036, 5-year impact factor: 4.665
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-77954960181&partnerID=40&md5=32034d04a14dafa665642826b88536d7
Keywords: 111in-Pentetreotide Scintigraphy, Indications, Neuroendocrine Tumours, Procedure Guidelines, Tumour Imaging, Dota Noc Ga 68, Dota Tate Ga 68, Dota Toc Ga 68, Gastrin, Glucagon, Glucose, Insulin, Pentetreotide In 111, Radioisotope, Radiopharmaceutical Agent, Somatostatin, Somatostatin Derivative, Somatostatin Receptor, Unclassified Drug, Diagnostic Agent, Drug Derivative, Age Distribution, Astrocytoma, Autoimmune Disease, Bacterial Infection, Breast, Breast Cancer, Breast Carcinoma, Breast Feeding, Cancer Chemotherapy, Cancer Localization, Cancer Radiotherapy, Cancer Staging, Cancer Surgery, Cecum, Colon, Diabetes Mellitus, Diabetic Patient, Diagnostic Accuracy, Diagnostic Imaging, Drug Accumulation, Drug Clearance, Drug Distribution, Drug Elimination, Drug Megadose, Drug Quality, Drug Receptor Binding, Drug Uptake, Drug Withdrawal, Endocrine Ophthalmopathy, False Negative Result, False Positive Result, Follow Up, Gallbladder, Ganglioneuroma, Gastrin Blood Level, Gastrinoma, Glucagon Blood Level, Glucagonoma, Glucose Metabolism, Granuloma, Human, Hypoglycemia, Hypophysis Adenoma, Image Analysis, Image Processing, Inflammatory Disease, Insulinoma, Intestine Injury, Kidney, Kidney Carcinoma, Kidney Dysfunction, Liver, Liver Metastasis, Lung Non Small Cell Cancer, Lung Small Cell Cancer, Lymphocyte, Medical Examination, Melanoma, Meningioma, Merkel Cell Tumor, Molecular Imaging, Neoplasm, Neuroblastoma, Nuclear Medicine, Paraganglioma, Parenteral Nutrition, Patient Monitoring, Patient Selection, Pheochromocytoma, Physician, Pleura, Practice Guideline, Pregnancy, Prognosis, Prostate Carcinoma, Protein Expression, Quality Control, Radiation Dose Distribution, Radioactivity, Radioisotope Therapy, Review, Sarcoma, Scintillation Camera, Single Photon Emission Computer Tomography, Spleen, Therapeutic Error, Thyroid Carcinoma, Thyroid Medullary Carcinoma, Treatment Contraindication, Treatment Indication, Tumor Differentiation, Tumor Scintiscanning, Undifferentiated Carcinoma, Urinary Excretion, Vipoma, Article, Computer Assisted Diagnosis, Female, Gene Expression Regulation, Genetics, Instrumentation, Methodology, Gamma Cameras, Neoplastic, Image Interpretation, Computer-Assisted, Radionuclide Imaging, Research Design,
Affiliations:
*** IBB - CNR ***
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Nuclear Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
University, Kocaeli, Turkey
PET Center, Bad Berka, Germany
CHUV, Lausanne, Switzerland
University of Naples, Naples, Italy
Ospedale di Legnano, Legnano, Italy
University UZ Gasthuisberg, Louvain, Belgium
Radboud University, Nijmegen, Netherlands
Istituto Clinico Humanitas, Milan, Italy
References:
Balon, H.R., Goldsmith, S.J., Siegel, B.A., Silberstein, E.B., Krenning, E.P., Lang, O., Procedure guideline for somatostatin receptor scintigraphy with (111) In-pentetreotide (2001) J. Nucl. Med., 42 (7), pp. 1134-113
Kwekkeboom, D.J., Krenning, E.P., Scheidhauer, K., Lewington, V., Lebtahi, R., Grossman, A., ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Somatostatin receptor imaging with (111)In-pentetreotide (2009) Neuroendocrinology, 90 (2), pp. 184-189
Lamberts, S.W., Bakker, W.H., Reubi, J.C., Krenning, E.P., Somatostatin-receptor imaging in the localization of endocrine tumors (1990) N. Engl. J. Med., 323 (18), pp. 1246-1249
Seregni, E., Chiti, A., Bombardieri, E., Radionuclide imaging of neuroendocrine tumours: Biological basis and diagnostic results (1998) Eur. J. Nucl. Med., 25 (6), pp. 639-658
Krenning, E.P., Kwekkeboom, D.J., Bakker, W.H., Breeman, W.A., Kooij, P.P., Oei, H.Y., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam expe-rience with more than 1000 patients (1993) Eur. J. Nucl. Med., 20 (8), pp. 716-731
Jamar, F., Fiasse, R., Leners, N., Pauwels, S., Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: Safety, efficacy and impact on patient management (1995) J. Nucl. Med., 36 (4), pp. 542-549
Olsen, J.O., Pozderac, R.V., Hinkle, G., Hill, T., O'Dorisio, T.M., Schirmer, W.J., Somatostatin receptor imaging of neuroendo-crine tumors with indium-111 pentetreotide (Octreoscan) (1995) Semin. Nucl. Med., 25 (3), pp. 251-261
Asnacios, A., Courbon, F., Rochaix, P., Bauvin, E., Cances-Lauwers, V., Susini, C., Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: New prognostic factors for malignant well-differentiated endocrine tumors (2008) J. Clin. Oncol., 26 (6), pp. 963-970
Wong, K.K., Cahill, J.M., Frey, K.A., Avram, A.M., Incremental value of 111-In pentetreotide SPECT/CT fusion imaging of neuroendo-crine tumors (2010) Acad. Radiol., 17, pp. 291-297
Steffen, I.G., Mehl, S., Heuck, F., Elgeti, F., Furth, C., Amthauer, H., Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: Is there an impact on sensitivity? (2009) Clin. Nucl. Med., 34 (12), pp. 869-873
Krausz, Y., Keidar, Z., Kogan, I., Even-Sapir, E., Bar-Shalom, R., Engel, A., SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours (2003) Clin. Endocrinol. (Oxf), 59 (5), pp. 565-573
Schillaci, O., Scopinaro, F., Angeletti, S., Tavolaro, R., Danieli, R., Annibale, B., SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors (1996) J. Nucl. Med., 37 (9), pp. 1452-1456
Warner, R.R., O'dorisio, T.M., Radiolabeled peptides in diagnosis and tumor imaging: Clinical overview (2002) Semin. Nucl. Med., 32 (2), pp. 79-83
Westlin, J.E., Janson, E.T., Arnberg, H., Ahlström, H., Oberg, K., Nilsson, S., Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide (1993) Acta Oncol., 32 (7-8), pp. 783-786
Schmidt, M., Scheidhauer, K., Luyken, C., Voth, E., Hildebrandt, G., Klug, N., Somatostatin receptor imaging in intracranial tumours (1998) Eur. J. Nucl. Med., 25 (7), pp. 675-686
Pichler, R., Pichler, J., Mustafa, H., Nussbaumer, K., Zaunmüller, T., Topakian, R., Somatostatin-receptor positive brain stem glioma visualized by octreoscan (2007) Neuro. Endocrinol. Lett., 28 (3), pp. 250-251
Kälkner, K.M., Janson, E.T., Nilsson, S., Carlsson, S., Oberg, K., Westlin, J.E., Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radioligand uptake and tumor markers (1995) Cancer Res., 55 (23 SUPPL.), pp. 5801s-5804s
Gibril, F., Reynolds, J.C., Doppman, J.L., Chen, C.C., Venzon, D.J., Termanini, B., Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study (1996) Ann. Intern. Med., 125 (1), pp. 26-34
Briganti, V., Sestini, R., Orlando, C., Bernini, G., La Cava, G., Tamburini, A., Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determina-tion of somatostatin receptor type 2 gene expression in neuroblastoma tumors (1997) Clin. Cancer Res., 3 (1-12 PT.), pp. 2385-2391
Chiti, A., Briganti, V., Fanti, S., Monetti, N., Masi, R., Bombardieri, E., Results and potential of somatostatin receptor imaging in gastro-enteropancreatic tract tumours (2000) Q J. Nucl. Med., 44 (1), pp. 42-49
Chiti, A., Fanti, S., Savelli, G., Romeo, A., Bellanova, B., Rodari, M., Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours (1998) Eur. J. Nucl. Med., 25 (10), pp. 1396-1403
Lebtahi, R., Cadiot, G., Sarda, L., Daou, D., Faraggi, M., Petegnief, Y., Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancre-atic tumors (1997) J. Nucl. Med., 38 (6), pp. 853-858
Khanna, G., O'Dorisio, M.S., Menda, Y., Glasier, C., Deyoung, B., Smith, B.J., Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies (2008) Pediatr. Blood Cancer, 50 (3), pp. 561-566
Kropp, J., Hofmann, M., Bihl, H., Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor? (1997) Anti-cancer Res., 17 (3 B), pp. 1583-1588
Radiation dose to patients from radio-pharmaceuticals (1998) Ann. ICRP, 28, p. 3. , ICRP Publication 80, Oxford: Pergamon
Radiological protection in biomedical research (1991) Ann. ICRP, 22, p. 3. , ICRP Publication 62, Oxford: Pergamon
(2008) Ann. ICRP, 38 (1-2), pp. 1-197. , Radiation dose to patients from radiopharmaceuticals, Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007
Sokole, E.B., Plachcínska, A., Britten, A., EANM working group on nuclear medicine instrumentation quality control, Lyra Georgosopoulou M, et al. Routine quality control recommendations for nuclear medicine instrumentation (2010) Eur. J. Nucl. Med. Mol. Imaging, 37, pp. 662-671. , EANM Physics Committee
Balon, H. R., Goldsmith, S. J., Siegel, B. A., Silberstein, E. B., Krenning, E. P., Lang, O., Procedure guideline for somatostatin receptor scintigraphy with (111) In-pentetreotide (2001) J. Nucl. Med., 42 (7), pp. 1134-113
Kwekkeboom, D. J., Krenning, E. P., Scheidhauer, K., Lewington, V., Lebtahi, R., Grossman, A., ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Somatostatin receptor imaging with (111) In-pentetreotide (2009) Neuroendocrinology, 90 (2), pp. 184-189
Lamberts, S. W., Bakker, W. H., Reubi, J. C., Krenning, E. P., Somatostatin-receptor imaging in the localization of endocrine tumors (1990) N. Engl. J. Med., 323 (18), pp. 1246-1249
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A., Kooij, P. P., Oei, H. Y., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1] -and [123I-Tyr3] -octreotide: The Rotterdam expe-rience with more than 1000 patients (1993) Eur. J. Nucl. Med., 20 (8), pp. 716-731
Olsen, J. O., Pozderac, R. V., Hinkle, G., Hill, T., O'Dorisio, T. M., Schirmer, W. J., Somatostatin receptor imaging of neuroendo-crine tumors with indium-111 pentetreotide (Octreoscan) (1995) Semin. Nucl. Med., 25 (3), pp. 251-261
Wong, K. K., Cahill, J. M., Frey, K. A., Avram, A. M., Incremental value of 111-In pentetreotide SPECT/CT fusion imaging of neuroendo-crine tumors (2010) Acad. Radiol., 17, pp. 291-297
Steffen, I. G., Mehl, S., Heuck, F., Elgeti, F., Furth, C., Amthauer, H., Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: Is there an impact on sensitivity? (2009) Clin. Nucl. Med., 34 (12), pp. 869-873
Warner, R. R., O'dorisio, T. M., Radiolabeled peptides in diagnosis and tumor imaging: Clinical overview (2002) Semin. Nucl. Med., 32 (2), pp. 79-83
Westlin, J. E., Janson, E. T., Arnberg, H., Ahlstr m, H., Oberg, K., Nilsson, S., Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1] -octreotide (1993) Acta Oncol., 32 (7-8), pp. 783-786
K lkner, K. M., Janson, E. T., Nilsson, S., Carlsson, S., Oberg, K., Westlin, J. E., Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radioligand uptake and tumor markers (1995) Cancer Res., 55 (23 SUPPL.), pp. 5801s-5804s
(2008) Ann. ICRP, 38 (1-2), pp. 1-197. , Radiation dose to patients from radiopharmaceuticals, Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007
Sokole, E. B., Plachc nska, A., Britten, A., EANM working group on nuclear medicine instrumentation quality control, Lyra Georgosopoulou M, et al. Routine quality control recommendations for nuclear medicine instrumentation (2010) Eur. J. Nucl. Med. Mol. Imaging, 37, pp. 662-671. , EANM Physics Committee
In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging
This document provides general information about somatostatin receptor scintigraphy with In-111-pentetreotide. This guideline should not be regarded as the only approach to visualise tumours expressing somatostatin receptors or as exclusive of other nuclear medicine procedures useful to obtain comparable results. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of In-111-pentetreotide scintigraphy.
This document provides general information about somatostatin receptor scintigraphy with In-111-pentetreotide. This guideline should not be regarded as the only approach to visualise tumours expressing somatostatin receptors or as exclusive of other nuclear medicine procedures useful to obtain comparable results. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of In-111-pentetreotide scintigraphy.
In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging
| ▼ A multi-targeting approach to fight COVID-19 |
| ▼ New peptide–based molecules as NGF mimetics in the therapy of neurological dysfunctions |
In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging
Other filter: ([btitle,keywords] "111in-Pentetreotide ...
Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A
* The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study (209 views)
Endocrine (ISSN: 1355-008xlinking), 2018 Oct; 62(1): 46-56.
Impact Factor: 3.179
View Export to BibTeX Export to EndNote
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
* Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours (495 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265), 2014 Jun; 80(6): 850-855.
Impact Factor: 3.457
View Export to BibTeX Export to EndNote
Darcourt J, Booij J, Tatsch K, Varrone A, Borght TV, Kapucu OL, Nagren K, Nobili F, Walker Z, Van Laere K
* EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version (723 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Feb; 37(2): 443-450.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, Darcourt J, Kapucu OL, Tatsch K, Bartenstein P, Van Laere K
* EANM procedure guidelines for PET brain imaging using [18F]FDG, version (633 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Dec; 36(12): 2103-2110.
Impact Factor: 4.531
View Export to BibTeX Export to EndNote
Zannetti A, Fonti R, Iommelli F, Papaccioli A, Sommella J, Tortora G, Bianco R, Salvatore M, Del Vecchio S
* SPECT imaging of endoplasmic reticulum-mediated tumor response to gefitinib and erlotinib in lung cancer (424 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2007 Oct; 34: 277-309.
Impact Factor: 4.101
View Export to BibTeX Export to EndNote
Ntziachristos V, Cuénod CA, Fournier L, Balvay D, Pradel C, Siauve N, Clement O, Jouannot E, Lucidarme O, Vecchio SD, Salvatore M, Law B, Tung C-H, Jain RK, Fukumura D, Munn LL, Brown EB, Schellenberger E, Montet X, Weissleder R, Clerck ND, Postnov A
* Tumor Imaging (350 views)
Textbook Of In Vivo Imaging In Vertebrates (ISSN: 9780-4700), 2007 Jul 16; 1: 277-309.
Impact Factor: 1.148
View Export to BibTeX Export to EndNote
Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K, Varrone A, Tatsch K
* EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues (522 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Nov; 33(11): 1374-1380.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Camera L, Bresciani M, Soscia E, Percopo V, Mainenti PP, Salvatore M
* Morphological imaging of gastroenteropancreatic neuroendocrine tumours (256 views)
Minerva Endocrinol (ISSN: 0391-1977, 1827-1634electronic, 0391-1977linking), 2001 Sep; 26(3): 123-128.
Impact Factor: 1.464
View Export to BibTeX Export to EndNote
* The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study (209 views)
Endocrine (ISSN: 1355-008xlinking), 2018 Oct; 62(1): 46-56.
Impact Factor: 3.179
View Export to BibTeX Export to EndNote
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
* Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours (495 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265), 2014 Jun; 80(6): 850-855.
Impact Factor: 3.457
View Export to BibTeX Export to EndNote
Darcourt J, Booij J, Tatsch K, Varrone A, Borght TV, Kapucu OL, Nagren K, Nobili F, Walker Z, Van Laere K
* EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version (723 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Feb; 37(2): 443-450.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, Darcourt J, Kapucu OL, Tatsch K, Bartenstein P, Van Laere K
* EANM procedure guidelines for PET brain imaging using [18F]FDG, version (633 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Dec; 36(12): 2103-2110.
Impact Factor: 4.531
View Export to BibTeX Export to EndNote
Zannetti A, Fonti R, Iommelli F, Papaccioli A, Sommella J, Tortora G, Bianco R, Salvatore M, Del Vecchio S
* SPECT imaging of endoplasmic reticulum-mediated tumor response to gefitinib and erlotinib in lung cancer (424 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2007 Oct; 34: 277-309.
Impact Factor: 4.101
View Export to BibTeX Export to EndNote
Ntziachristos V, Cuénod CA, Fournier L, Balvay D, Pradel C, Siauve N, Clement O, Jouannot E, Lucidarme O, Vecchio SD, Salvatore M, Law B, Tung C-H, Jain RK, Fukumura D, Munn LL, Brown EB, Schellenberger E, Montet X, Weissleder R, Clerck ND, Postnov A
* Tumor Imaging (350 views)
Textbook Of In Vivo Imaging In Vertebrates (ISSN: 9780-4700), 2007 Jul 16; 1: 277-309.
Impact Factor: 1.148
View Export to BibTeX Export to EndNote
Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K, Varrone A, Tatsch K
* EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues (522 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Nov; 33(11): 1374-1380.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Camera L, Bresciani M, Soscia E, Percopo V, Mainenti PP, Salvatore M
* Morphological imaging of gastroenteropancreatic neuroendocrine tumours (256 views)
Minerva Endocrinol (ISSN: 0391-1977, 1827-1634electronic, 0391-1977linking), 2001 Sep; 26(3): 123-128.
Impact Factor: 1.464
View Export to BibTeX Export to EndNote
8 Records (8 excluding Abstracts).
Total impact factor: 26.957 (26.957 excluding Abstracts).
Total 5 year impact factor: 26.179 (26.179 excluding Abstracts).
Total impact factor: 26.957 (26.957 excluding Abstracts).
Total 5 year impact factor: 26.179 (26.179 excluding Abstracts).
479 views. Last view on Saturday 14 January 2023, 18:57:57
ibb.cnr.it
